BioPharma

13 October, 2026 | Tuesday | News

Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA

Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for the rest of the world. The deal includes 15 million US d...

Lab

13 October, 2026 | Tuesday | News

CellCarta Partners with Waters Corporation to Advance Companion Diagnostics and Next-Generation Flow Cytometry

CellCarta, a leading global CRO laboratory to the biopharmaceutical industry,  announced a strategic partnership with Waters Corporation, a global leader in life sciences and diagnostics, creating a framew...

BioTech

12 October, 2026 | Monday | News

Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bi...

Contract Services

13 October, 2026 | Tuesday | News

LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership with Alvotech to increase their global manufacturing ...

Consumer Health

09 October, 2026 | Friday | Analysis

Semaglutide Generics, Six Months In: Every Launch in India, Every Price, and Where China Stands

AT A GLANCE 12 generic makers with a public launch in India, selling 20 brands between them Rs 1,290 lowest stated monthly price, for vials from Natco and Eris 3x the premium Natco and Eri...

Medtech

12 October, 2026 | Monday | News

RingConn Smart Ring Secures US FDA 510(k) Clearance for Non-Invasive Blood Oxygen Monitoring

Shenzhen Ninenovo Technology Limited, the parent company of RingConn, announced that its Smart Ring has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for non-invasive blood oxygen (...

Cell & Gene

13 October, 2026 | Tuesday | News

Nuevocor Doses First Patient in Phase 1/2 Gene Therapy Trial for Inherited Cardiomyopathy

 Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, announced that the first patient has...


Biopharma APAC Infomercial

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close